BDG
0.092
84%
MHK
0.175
-53.9%
OLI
0.009
80%
AQC
0.009
-40%
BSA
0.13
78.1%
GTN
0.365
-38.7%
PIM
0.065
62.5%
GMN
0.057
-37.4%
1AE
0.077
60.4%
XPN
0.008
-33.3%
HCT
0.11
50.7%
LM1
0.099
-31.7%
I88
0.17
41.7%
RPG
0.165
-31.3%
CYQ
0.004
33.3%
SS1
0.76
-29.6%
GTR
0.004
33.3%
SYR
0.27
-28%
IMI
0.012
33.3%
CDE
0.019
-26.9%
LKY
0.14
33.3%
DTM
0.003
-25%
PXX
0.012
33.3%
RGL
0.003
-25%
RMY
0.04
33.3%
ROG
0.003
-25%
CMB
0.425
32.8%
GGP
5.18
-24.8%
IAM
0.038
31%
CTT
0.275
-24.7%
BCA
0.345
30.2%
CGR
0.05
-23.1%
MGU
0.009
28.6%
3DP
0.047
-23%
4DX
0.305
27.1%
YRL
0.12
-22.6%
X2M
0.019
26.7%
ANR
0.007
-22.2%
ART
0.36
26.3%
PLC
0.007
-22.2%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Arovella Therapeutics (ASX:ALA): A novel cell therapy treatment for cancers and tumours

Ahead of appearing at the Spark+ Australian Equities Day in Singapore, Arovella’s (ASX:ALA) CEO & Managing Director Dr Michael Baker speaks with The Stock Network’s Lel Smits about:

🩸 The current lead product coming out of Arovella Therapeutics’ cell therapy platform – ALA-101 – iNKT cells create receptors that target antigens
🩸 How ALA-101 targets cancers and tumours
🩸 Timing of Phase 1 trials for ALA-101

Watch the full interview ⚡️ https://youtu.be/Hb_HZmKYCNA
Register to attend Australian Equities Day: https://www.eventbrite.sg/e/spark-plus-australian-equities-day-tickets-939180011697

Write to us
  • © 2025 Copyright
  • The Stock Network
  • All rights reserved